Yasuko Ichikawa

942 total citations
39 papers, 582 citations indexed

About

Yasuko Ichikawa is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Yasuko Ichikawa has authored 39 papers receiving a total of 582 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 6 papers in Molecular Biology. Recurrent topics in Yasuko Ichikawa's work include Lung Cancer Treatments and Mutations (8 papers), Colorectal Cancer Treatments and Studies (5 papers) and Lung Cancer Research Studies (5 papers). Yasuko Ichikawa is often cited by papers focused on Lung Cancer Treatments and Mutations (8 papers), Colorectal Cancer Treatments and Studies (5 papers) and Lung Cancer Research Studies (5 papers). Yasuko Ichikawa collaborates with scholars based in Japan, United States and India. Yasuko Ichikawa's co-authors include Hideyuki Saya, Norihiko Tamaki, Toru Hirota, Yukio Okano, Tatsuyuki Mimori, Takashi Sasayama, Masashi Kimura, Tetsuro Morisaki, Dongwei Zhang and Shinji Kuninaka and has published in prestigious journals such as Journal of Biological Chemistry, Scientific Reports and Japanese Journal of Applied Physics.

In The Last Decade

Yasuko Ichikawa

37 papers receiving 573 citations

Peers

Countries citing papers authored by Yasuko Ichikawa

Since Specialization

Citations

This map shows the geographic impact of Yasuko Ichikawa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yasuko Ichikawa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yasuko Ichikawa more than expected).

Fields of papers citing papers by Yasuko Ichikawa

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yasuko Ichikawa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yasuko Ichikawa. The network helps show where Yasuko Ichikawa may publish in the future.

Co-authorship network of co-authors of Yasuko Ichikawa

This figure shows the co-authorship network connecting the top 25 collaborators of Yasuko Ichikawa. A scholar is included among the top collaborators of Yasuko Ichikawa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yasuko Ichikawa. Yasuko Ichikawa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Clinical Features of Pneumocystis Pneumonia in Non-Human Immunodeficiency Virus-Infected Patients: A Systemic Review and Meta-Analysis 2024 ·Masashi Ishihara, (unknown), Takeshi Honda, Yasuko Ichikawa, Kiyotaka Watanabe, Nobuhiko Seki	0
2	Efficacy and safety of pharmacotherapy for cancer cachexia: A systematic review and network meta‐analysis 2024 ·Cancer Medicine ·Hao Chen, Masashi Ishihara, (unknown), (unknown), (unknown), (unknown), Yasuko Ichikawa, Nobuyuki Horita, Hisashi Nagai, Kiyotaka Watanabe, Nobuhiko Seki	4
3	Predictors of central line-associated bloodstream infections in cancer patients undergoing chemotherapy through implanted venous access ports: a retrospective, observational study 2023 ·Translational Cancer Research ·Hao Chen, (unknown), (unknown), Masashi Ishihara, (unknown), Takahiko Sakamoto, (unknown), (unknown), Yasuko Ichikawa, Kiyotaka Watanabe, Nobuhiko Seki	1
4	Multicenter, single-arm phase II study of modified carboplatin/nab-paclitaxel in untreated performance status 2 patients with advanced non-small cell lung cancer: TORG1426 2023 ·Translational Cancer Research ·Yasuko Ichikawa, Nobuhiko Seki, Takeshi Honda, (unknown), Shinobu Hosokawa, Akihiro Bessho, (unknown), Tsuneo Shimokawa, Sakiko Otani, Yoshiro Nakahara, Katsuhiko Naoki, Makiko Yomota, Yukio Hosomi, Yuichi Takiguchi, Takaaki Tokito, Shuji Ando, Hiroaki Okamoto	1
5	Pretreatment neutrophil-to-lymphocyte ratio predicts treatment efficacy and prognosis of cytotoxic anticancer drugs, molecular targeted drugs, and immune checkpoint inhibitors in patients with advanced non-small cell lung cancer 2021 ·Translational Lung Cancer Research ·Masashi Ishihara, (unknown), (unknown), Takahiko Sakamoto, (unknown), Takeshi Honda, Shuji Ota, Yasuko Ichikawa, Tsuyoshi Ishida, Kiyotaka Watanabe, Nobuhiko Seki	9
6	Carcinoma of Unknown Primary Site: A Mini-Review on Chemotherapy and the Expectation for Treatment with Nab-Paclitaxel Plus Carboplatin 2019 ·Yasuko Ichikawa, (unknown), (unknown), Masashi Ishihara, (unknown), Takahiko Sakamoto, (unknown), (unknown), Shuji Ota, Kiyotaka Watanabe, Nobuhiko Seki, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	1
7	Promising Combination Therapy with Bevacizumab and Erlotinib in an EGFR-Mutated NSCLC Patient with MET Amplification Who Showed Intrinsic Resistance to Initial EGFR-TKI Therapy 2019 ·Case Reports in Oncology ·Nobuhiko Seki, (unknown), (unknown), (unknown), Masashi Ishihara, (unknown), Takahiko Sakamoto, (unknown), (unknown), Takeshi Honda, Shuji Ota, Yasuko Ichikawa, Kiyotaka Watanabe	6
8	Need for Flexible Adjustment of the Treatment Schedule for Aprepitant Administration against Erlotinib-Induced Refractory Pruritus and Skin Rush 2019 ·Case Reports in Oncology ·Nobuhiko Seki, (unknown), (unknown), Masashi Ishihara, (unknown), (unknown), Takahiko Sakamoto, (unknown), (unknown), Takeshi Honda, Shuji Ota, Yasuko Ichikawa, Kiyotaka Watanabe	2
9	Significance of Earlier Initiation of Chemotherapy for Lung Cancer Complicated with Primary or Secondary Nephrotic Syndrome following Its Appropriate Differential Diagnosis 2019 ·Case Reports in Oncology ·Shuji Ota, Yoshihide Fujigaki, Yoshifuru Tamura, Kenichiro Kojima, (unknown), (unknown), Masashi Ishihara, (unknown), (unknown), Takahiko Sakamoto, (unknown), (unknown), Takeshi Honda, Yasuko Ichikawa, Kiyotaka Watanabe, Nobuhiko Seki	1
10	A Patient with Advanced Gastric Cancer Who Achieved a Long-Term Prognosis by Early Diagnosis of Sister Mary Joseph’s Nodule 2018 ·Case Reports in Oncology ·Shuji Ota, (unknown), Masashi Ishihara, (unknown), (unknown), Takahiko Sakamoto, (unknown), (unknown), Takeshi Honda, Yasuko Ichikawa, Kiyotaka Watanabe, Yuko Sasajima, Nobuhiko Seki	3
11	A Case of Lung Adenocarcinoma with Marked Improvement of Pulmonary Lymphangitic Carcinomatosis by Adding Bevacizumab to Cisplatin and Pemetrexed 2017 ·Case Reports in Oncology ·(unknown), Takeshi Honda, (unknown), Masashi Ishihara, (unknown), Takahiko Sakamoto, (unknown), (unknown), Shuji Ota, Yasuko Ichikawa, Kiyotaka Watanabe, Nobuhiko Seki	4
12	Dose-escalation study of pemetrexed in combination with carboplatin followed by pemetrexed maintenance therapy for advanced non-small cell lung cancer 2010 ·Lung Cancer ·Isamu Okamoto, Koji Takeda, Haruko Daga, Masaki Miyazaki, Kimio Yonesaka, (unknown), Junji Tsurutani, Shinya Ueda, Yasuko Ichikawa, Masayuki Takeda, (unknown), (unknown), Sotaro Enatsu, Yoshihiro Nambu, Kazuhiko Nakagawa	8
13	Feasibility study of two schedules of sunitinib in combination with pemetrexed in patients with advanced solid tumors 2010 ·Investigational New Drugs ·Isamu Okamoto, Toshio Shimizu, Masaki Miyazaki, Junji Tsurutani, Yasuko Ichikawa, (unknown), Masayuki Takeda, Soichi Fumita, Emiko Ohki, Nobuyuki Kimura, Junichi Hashimoto, Kazuhiko Nakagawa	8
14	Retreatment of recurrent malignant pleural mesothelioma with cisplatin and pemetrexed 2010 ·International Journal of Clinical Oncology ·Hidetoshi Hayashi, Isamu Okamoto, Yasuko Ichikawa, Masaki Miyazaki, Hiroshige Yoshioka, Kei Kunimasa, Kazuhiko Nakagawa	9
15	The Neurofibromatosis Type 1 Gene Product Neurofibromin Enhances Cell Motility by Regulating Actin Filament Dynamics via the Rho-ROCK-LIMK2-Cofilin Pathway 2005 ·Journal of Biological Chemistry ·Tatsuya Ozawa, Norie Araki, Shunji Yunoue, Hiroshi Tokuo, Liping Feng, (unknown), Toshihiro Hara, Yasuko Ichikawa, Kunio Matsumoto, Kiyotaka Fujii, Hideyuki Saya	59
16	Efficacy of the tyrosine kinase inhibitor gefitinib in a patient with metastatic small cell lung cancer 2004 ·Lung Cancer ·Jun Araki, Isamu Okamoto, Ryuichiro Suto, Yasuko Ichikawa, Ji-ichiro Sasaki	35
17	Work Related to Investigations Right after the Marketing of Drugs in a Medical Institution: The Role of Pharmacists and the Corresponding Man Power and Cost 2003 ·Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) ·(unknown), Hiroyuki Kuwano, (unknown), Yasuko Ichikawa, (unknown), (unknown), Masahiro Fukuoka	1
18	Expression of constitutively activated EGFRvlll in non‐small cell lung cancer 2003 ·Cancer Science ·Isamu Okamoto, Lawrence C. Kenyon, David R. Emlet, Takeshi Mori, (unknown), Susumu Hirosako, Yasuko Ichikawa, Hiroto Kishi, Andrew K. Godwin, Masakazu Yoshioka, Moritaka Suga, Mitsuhiro Matsumoto, Albert J. Wong	107
19	A case of nocardia brain abscesses in a hemodialysis patient treated with prednisolone 2003 ·Nihon Toseki Igakkai Zasshi ·Yoshihiro Takebayashi, (unknown), Keiko Nakajima, Takao Suga, Yasuko Ichikawa, Akira Saitō	1
20	Roles of aurora‐A kinase in mitotic entry and G2 checkpoint in mammalian cells 2002 ·Genes to Cells ·Tomotoshi Marumoto, Toru Hirota, Tetsuro Morisaki, Naoko Kunitoku, Dongwei Zhang, Yasuko Ichikawa, Takashi Sasayama, Shinji Kuninaka, Tatsuyuki Mimori, Norihiko Tamaki, Masashi Kimura, Yukio Okano, Hideyuki Saya	182

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact